Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2022-11, Vol.140 (Supplement 1), p.1716-1719
Hauptverfasser:	Liu, Hongtao, Sharon, Elad, Karrison, Theodore G., Zha, Yuanyuan, Fulton, Noreen, Streicher, Howard, Sweet, Kendra, Yaghmour, George, Liu, Jane Jijun, Jonas, Brian A., Schimmer, Aaron D., Grant, Steven, Zeidan, Amer M., Hildebrandt, Gerhard C., Hourigan, Christopher S., Lowrey, Christopher H., Mattison, Ryan J., Palmisiano, Neil, Salhotra, Amandeep, Tzachanis, Dimitrios, Baer, Maria R., Lin, Tara L., Patel, Prapti, Chen, Helen, Stadler, Walter M., Odenike, Olatoyosi, Larson, Richard A., Gajewski, Thomas F., Stock, Wendy
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!